FDA panel supports broadening access to peptides popular on the gray market

An FDA advisory committee has voted to recommend easing restrictions on several popular peptides, a move that could shift how these compounds are produced and accessed in the United States. While the agency itself has raised concerns about limited safety data, the advisory panel supported broadening production rights for specialized pharmacies to handle substances like BPC-157, KPV, MOTS-c, and TB-500.

These peptides are widely used for purposes including injury recovery, athletic performance, and metabolic health. Currently, many consumers acquire these substances through the gray market, often accompanied by warnings that they are for research only. Proponents of the policy change argue that allowing licensed pharmacies to produce these compounds provides a safer pathway for patients who seek these therapies under medical supervision.

FDA scientists maintained their position that more rigorous data is necessary to prove the safety and efficacy of these drugs. They noted that the lack of clear chemical definitions for these substances complicates the establishment of quality standards. Despite these warnings, the panel members voted in favor of the expansion, signaling a departure from the current regulatory stance.

The committee's decision follows a two-day review process. Although the FDA is not legally obligated to follow its advisory panel's recommendations, it typically acts in alignment with them. This potential reclassification is a win for industry groups and clinicians who emphasize that patients are already using these substances and would benefit from improved regulatory oversight. The committee continues its review of additional compounds in the coming days.